Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study (ROLFH)

This study has been withdrawn prior to enrollment.
(Unable to obtain funding)
Sponsor:
Collaborators:
University of North Carolina, Chapel Hill
University of Toronto
University of Calgary
Information provided by (Responsible Party):
University of Arkansas
ClinicalTrials.gov Identifier:
NCT01831037
First received: April 2, 2013
Last updated: January 27, 2015
Last verified: January 2015
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: December 2019
  Estimated Primary Completion Date: June 2019 (Final data collection date for primary outcome measure)